A Phase 3 interventional study of Dexmedetomidine hydrochloride and Placebo in Sedation, sponsored by Pfizer. Completed at 12 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-03-22.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to examine the efficacy and safety of DA-9501 (Dexmedetomidine) in patients who require sedation during the surgery that requires epidural or spinal anesthesia without intubation under monitored sedation care.
Phase III, randomized, placebo controlled, double blind, parallel comparative study (Therapeutic confirmatory trial), to evaluate the efficacy and the safety of Dexmedetomidine in non-intubated patients who require sedation during surgery with spinal or epidural anesthesia under monitored sedation care
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose
Drug: Placebo
Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
Drug: Dexmedetomidine hydrochloride
Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
Drug: Dexmedetomidine hydrochloride
Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
Drug: Dexmedetomidine hydrochloride
Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
Drug: Dexmedetomidine hydrochloride
Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration.
Time frame: Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.
Number of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration
Time frame: 15 minutes after the start of study drug, if the OAA/S score is 5.
Dosage of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration
Time frame: 15 minutes after the start of study drug, if the OAA/S score is 5.
Time to First Rescue Administration of Propofol
Time frame: During the study drug infusion period (≥15 minutes [Approximate])
Percentage of Patients Who Did Not Require Rescue Administration of Fentanyl During the Study Drug Administration
Time frame: After the surgery start, the administration of fentanyl is permissible as required to treat pain. In case of repeated dose, the dosing interval should be ≥15 minutes.
Number of Fentanyl Dosing Required During the Study Drug Administration.
Time frame: During the study drug administration
Dosage of Fentanyl Dosing Required During the Study Drug Administration.
Time frame: During the study drug administration
Percentage of Time Spent OAA/S Score ≤4 During the Study Drug Infusion
Time frame: Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.
Percentage of Time Spent OAA/S Score 3 to 4 During the Study Drug Infusion
Time frame: Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.
Time to Attain the Point Where Patient is Recovered Assessed by Aldrete Score Following Discontinuation of the Study Drug Infusion
Time frame: Every 15 ± 2 minutes until the score of each item becomes ≥1 and the total value becomes ≥8.
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Easiness of Maintenance of Sedation Level)
VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Hemodynamic State)
VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Respiratory State)
VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration
Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Subject's Cooperation)
VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration
Score Evaluation of Satisfaction and Anxiety of the Subject ("I Was Satisfied With This Anesthesia Procedure")
Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration (as much as possible)
Score Evaluation of Satisfaction and Anxiety of the Subject ("I Did Not Feel Pain During the Surgery")
Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration (as much as possible)
Score Evaluation of Satisfaction and Anxiety of the Subject ("If You May Undergo a Similar Surgery, the Same Anesthesia Procedure Will be Requested for the Next Time")
Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration (as much as possible)
Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level Before Surgery")
Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration (as much as possible)
Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level During Surgery")
Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration (as much as possible)
Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level After Surgery")
Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.
Time frame: Within 24 hours after completion of the study drug administration (as much as possible)
| Milestone | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Started | 22 | 23 | 24 | 25 | 25 |
| Completed | 21 | 22 | 24 | 24 | 25 |
| Not completed | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 1 | 0 |
| Percentage of participants | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration. | 22.7 (7.8 to 45.4) | 13.0 (2.8 to 33.6) | 45.8 (25.6 to 67.2) | 68.0 (46.5 to 85.1) | 80.0 (59.3 to 93.2) |
| Number of dosing | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Number of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration | 5.1 ± 4.7 | 3.7 ± 3.4 | 1.9 ± 2.3 | 0.8 ± 1.5 | 0.5 ± 1.2 |
| mg/kg | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Dosage of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration | 1.019 ± 0.933 | 0.744 ± 0.675 | 0.373 ± 0.459 | 0.166 ± 0.298 | 0.096 ± 0.231 |
| minutes | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Time to First Rescue Administration of Propofol | 25.5 (20.0 to 46.0) | 20 (20.0 to 22.0) | 24 (21.0 to NA) | NA (61.0 to NA) | NA (NA to NA) |
| Percentage of participants | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Percentage of Patients Who Did Not Require Rescue Administration of Fentanyl During the Study Drug Administration | 95.5 (77.2 to 99.9) | 91.3 (72.0 to 98.9) | 100.0 (85.8 to 100.0) | 96.0 (79.6 to 99.9) | 96.0 (79.6 to 99.9) |
| Number of dosing | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Number of Fentanyl Dosing Required During the Study Drug Administration. | 0.1 ± 0.6 | 0.2 ± 0.7 | 0.0 ± 0.0 | 0.0 ± 0.2 | 0.1 ± 0.6 |
| mcg/kg | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Dosage of Fentanyl Dosing Required During the Study Drug Administration. | 0.068 ± 0.320 | 0.085 ± 0.317 | 0.000 ± 0.000 | 0.018 ± 0.088 | 0.061 ± 0.304 |
| Percentage of time | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Percentage of Time Spent OAA/S Score ≤4 During the Study Drug Infusion | 50.17 ± 23.88 | 58.15 ± 20.71 | 61.44 ± 18.28 | 70.07 ± 21.08 | 76.78 ± 14.07 |
| Percentage of time | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Percentage of Time Spent OAA/S Score 3 to 4 During the Study Drug Infusion | 47.88 ± 25.31 | 56 ± 19.87 | 53.66 ± 17.5 | 65.3 ± 20.63 | 62.25 ± 23.14 |
| Minutes | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Time to Attain the Point Where Patient is Recovered Assessed by Aldrete Score Following Discontinuation of the Study Drug Infusion | 15 (NA to NA) | 15 (NA to NA) | 15 (15.0 to 16.0) | 15 (NA to NA) | 15 (NA to NA) |
VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Easiness of Maintenance of Sedation Level) | 5.85 ± 3.54 | 4.36 ± 3.41 | 3.73 ± 3.19 | 2.81 ± 2.64 | 2.65 ± 2.98 |
VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Hemodynamic State) | 2.05 ± 2.21 | 3.3 ± 3.19 | 1.68 ± 1.46 | 1.72 ± 2.14 | 1.47 ± 1.41 |
VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Respiratory State) | 2.35 ± 2.77 | 2.62 ± 2.79 | 1.8 ± 2.02 | 2.85 ± 2.9 | 3.12 ± 2.13 |
VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Subject's Cooperation) | 1.48 ± 1.67 | 1.8 ± 2.35 | 1.05 ± 1.46 | 1.15 ± 1.19 | 1.17 ± 1.46 |
Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Score Evaluation of Satisfaction and Anxiety of the Subject ("I Was Satisfied With This Anesthesia Procedure") | 1.7 ± 0.8 | 1.7 ± 1 | 1.2 ± 0.4 | 1.4 ± 0.7 | 1.3 ± 0.7 |
Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Score Evaluation of Satisfaction and Anxiety of the Subject ("I Did Not Feel Pain During the Surgery") | 1.2 ± 0.7 | 1.2 ± 0.7 | 1.2 ± 0.7 | 1.4 ± 0.9 | 1.2 ± 0.6 |
Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Score Evaluation of Satisfaction and Anxiety of the Subject ("If You May Undergo a Similar Surgery, the Same Anesthesia Procedure Will be Requested for the Next Time") | 1.7 ± 1.1 | 1.5 ± 0.8 | 1.3 ± 0.6 | 1.5 ± 0.8 | 1.2 ± 0.4 |
Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level Before Surgery") | 2.2 ± 1.3 | 2.2 ± 1.3 | 2.2 ± 1.2 | 1.8 ± 1 | 2 ± 1.2 |
Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level During Surgery") | 1.6 ± 1.1 | 1.6 ± 0.8 | 1.6 ± 0.9 | 1.4 ± 0.9 | 1.7 ± 1.1 |
Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.
| Scores on a scale | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Score Evaluation of Satisfaction and Anxiety of the Subject ("Assess the Anxiety Level After Surgery") | 1.6 ± 0.9 | 1.6 ± 1 | 1.6 ± 0.6 | 1.3 ± 0.7 | 1.5 ± 1 |
Collected over Adverse events that occurred from the start of treatment to 24 hours after the end of treatment, a median of 67 - 87 mins treatment depending on treatment arms.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/22 (0%) | 0/22 (0%) | 19/22 (86.4%) |
| Dexmedetomidine 0.067 mcg/kg | 0/23 (0%) | 1/23 (4.3%) | 21/23 (91.3%) |
| Dexmedetomidine 0.25 mcg/kg | 0/24 (0%) | 0/24 (0%) | 24/24 (100%) |
| Dexmedetomidine 0.5 mcg/kg | 0/25 (0%) | 0/25 (0%) | 22/25 (88%) |
| Dexmedetomidine 1.0 mcg/kg | 0/25 (0%) | 0/25 (0%) | 25/25 (100%) |
| Event | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| SepsisInfections and infestations | 0/22 | 1/23 | 0/24 | 0/25 | 0/25 |
| Event | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg |
|---|---|---|---|---|---|
| Respiratory depressionRespiratory, thoracic and mediastinal disorders | 12/22 | 11/23 | 12/24 | 10/25 | 11/25 |
| HypotensionVascular disorders | 5/22 | 12/23 | 11/24 | 8/25 | 10/25 |
| BradycardiaCardiac disorders | 8/22 | 11/23 | 9/24 | 10/25 | 11/25 |
| HypertensionVascular disorders | 5/22 | 2/23 | 2/24 | 3/25 | 8/25 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 4/22 | 3/23 | 2/24 | 3/25 | 3/25 |
| GlossoptosisGastrointestinal disorders | 3/22 | 0/23 | 0/24 | 2/25 | 2/25 |
| TachycardiaCardiac disorders | 2/22 | 3/23 | 0/24 | 0/25 | 0/25 |
| HeadachesNervous system disorders | 2/22 | 1/23 | 0/24 | 1/25 | 0/25 |
| NauseaGastrointestinal disorders | 2/22 | 0/23 | 1/24 | 0/25 | 1/25 |
| Puncture site painGeneral disorders | 2/22 | 0/23 | 1/24 | 0/25 | 0/25 |
Full Analysis Set\<FAS\>: FAS is defined as all patients who were administered with the study drugs.
| Age, Continuous(years) | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg | Total |
|---|---|---|---|---|---|---|
| Mean | 69.0 (51 to 86) | 60.7 (33 to 85) | 63.8 (27 to 86) | 60.0 (28 to 80) | 59.3 (26 to 82) | 62.4 (26 to 86) |
| Sex: Female, Male(Participants) | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 7 | 8 | 7 | 13 | 38 |
| Male | 19 | 16 | 16 | 18 | 12 | 81 |
| Race (NIH/OMB)(Participants) | Placebo | Dexmedetomidine 0.067 mcg/kg | Dexmedetomidine 0.25 mcg/kg | Dexmedetomidine 0.5 mcg/kg | Dexmedetomidine 1.0 mcg/kg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 22 | 23 | 24 | 25 | 25 | 119 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
Ran from Jun 2011 to primary completion in Nov 2011, 5 months.
Results were first posted in Mar 2021, 9 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine